There were 361 open cases of claims of misconduct against persons – including sexual misconduct and other forms of harassment – in WHO worldwide, as of end August: WHO Dashboard

More sexual misconduct and abusive claims were filed against WHO staff, than closed, over the previous month – with 361 open cases in 2026, as of the beginning of September, according to the agency’s own investigations dashboard.

In August, the last month reported, investigators opened 37 new sexual and abusive conduct cases and closed 25 – representing a 25% increase in the queue in just the past month. The overall pace of case openings is running at an average of 28 a month, according to the WHO misconduct dashboard, run by the Office of Internal Oversight Services (IOS).

The data coincides with anecdotal staff reports of lagging investigations and an internal WHO auditor’s review reporting months of delay in case resolution and closures in 2025 – well beyond the three month/120 day target for investigations set by WHO following reforms made after the 2020 sexual harassment and abuse scandal involving WHO and UN staff and contractors, which surfaced in the Democratic Republic of Congo. 

Incorrect data on trends: WHO has acknowledged but failed to correct

Incorrect data on overall trends – which WHO has acknowledged but so far failed to correct – confounds any complete reading on how and where new cases are rising overall. 

“IOS’s abuse dashboards are actively reporting demonstrably false data. As of October 7, WHO finally flagged the charts for verification and added a brief note to the dashboard. It took external intervention to get action,” said Kieran Bligh, a global health researcher at George Washington University in a LinkedIn post.

“So far in 2026, only six sexual and abusive conduct cases have resulted in substantiated disciplinary decisions,” he added, citing WHO’s own reports. “Four involved senior personnel. Not one was dismissed.” 

Queried repeatedly by Health Policy Watch over the past week, WHO posted a note on the dashboard pointing to the errors, but failed to provide any further clarification about the data and trends.

Recruitment of new IOS Director pending

The imbroglio coincides with the WHO’s recruitment of a new IOS director, following the recent retirement of Lisa McClennon who held the post since 2023. 

Currently,  Malika Parent-AiT-Mohamed is serving as acting director – and may be a candidate for the fixed term post.  However, in light of the reportedly high rate of complaints, backlog of cases, and the sensitivity of the post, critics like Bligh, have called for more active supervision of the candidate selection process by the Executive Board.  

Among the seven contenders that have so far emerged since nominations closed on 24 September, only one has publicly addressed the issue. 

George Tamamyan, an Armenian oncologist nominated by Botswana, had his campaign team  analyse publicly available data in the May 2026 Internal Auditor’s report. In a lengthy LinkedIn post, he called upon victims and critics to approach him personally on the issue, saying:  

“What we found deserves a serious conversation. WHO reported that its investigations function handled 1,174 cases in 2025 and closed 636, leaving 538 at year-end….WHO says that timeliness, responsiveness and fairness in misconduct investigations are essential to maintaining trust. I agree!   

Declining case closures?

The ‘other’ category of WHO offices, typically referring to WHO’s Global Service Center, Kuala Lumpur, Malaysia, reported the highest number of sexual misconduct cases over the past 12 months.

What seems clear  is that over the past 12 months, a total of 336 cases of sexual misconduct or abusive conduct cases were filed across all WHO regions – with the lion’s share in Africa (69) and the Eastern Mediterranean Region (81). 

The same three topped the table in 2023, in the same order. Roughly a quarter of all open cases concern sexual misconduct. In Africa it is close to half.

“Other” WHO offices (typically referring to WHO’s global service center in Kuala Lumpur) and Headquarters ranked third and fourth in the number of sexual and general misconduct cases filed, with 27 sexual misconduct cases in the “other” category – the most of any.   

Fewer sexual misconduct and abusive conduct cases were closed in 2026 and 2025, as compared to 2024 – although far more than in 2021 and 2022, when the initial DRC revelations came to light. 

Sexual harassment in 2026 complaints outpace last year’s

WHO dashboard shows an uptick in sexual harrassment complaints in the first three quarters of 2026, as compared to all of 2025.

And with one-third of the year yet to be recorded, sexual harassment complaints had already passed last year’s total of 25, with a third of the year still to run.

Twenty months for a four-month job

WHO Internal Auditor Report to the May 2026 Assembly

In 2025, a sexual misconduct investigation took 20 months on average. WHO’s target is four, according to the  Internal Auditor’s report to the World Health Assembly in May. The wait was five months longer than a year earlier.

Abusive conduct, which covers harassment, discrimination and abuse of authority, was slower still. Together with financial cases it averaged 34 months against a target of six, according to the auditor’s report to the May 2026 World Health Assembly.

The office doing the work is shrinking. During the massive budget cuts seen over the past year, it discontinued nine vacant posts and ended 12 consultancy contracts, leaving 10.5 budgeted staff posts and about 10 full-time consultants. Along with the current screening for a permanent head of IOS, candidates for the permanent position of Head of Investigations.

“Overreliance on external investigators directly exposes cases at intake or investigation to delays owing to mandatory breaks in consultant contracts, natural attrition and turnover,” the auditors wrote. They called the caseload “not sustainable” under the current model.

The report also logged a steep fall in new sexual misconduct cases, to 48 in 2025 from 99 in 2024 and 172 two years before. Among the possible explanations it offered was “shifting attention and pressures” caused by WHO’s own restructuring. 

But this year’s dashboard numbers, however incomplete, suggest the lull could be over.

“Justice delayed is justice denied”

Internal report to the 2026 WHA on all types of misconduct, open and closed cases

Staff representatives have long complained about delays in WHO’s internal justice process. 

“Delays in justice processes not only undermine confidence in the system but also contribute to stress, disengagement and a sense of vulnerability among staff,” the WHO Staff Associations told the Executive Board at their meeting in February 2026. “As the saying goes, justice delayed is justice denied.”

The promise they are measuring against dates from the sex-for-jobs scandal in the Democratic Republic of Congo during the 2018–2020 Ebola response, when WHO admitted its failures and WHO Director General Dr Tedros Adhanom Gheybreysus pledged zero tolerance for abuse cases.

On a visit to the Goma, DRC in November 2022, then-WHO official Gaya Gamhewage committed to supporting survivors of sexual assault of the Ebola outbreak.

By May 2023, WHO was presenting the problem as under control. Its dashboard that month said a dedicated team had “cleared the SEA/SH backlog” and that sexual misconduct cases were being “worked in real time”, with “an end-to-end investigative process of 120 days”. It showed 426 open cases.

“WHO is committed to transparency in its zero tolerance approach to sexual misconduct,” the UN’s health body said during investigations of DRC abuses.

But three years on, the open count has fallen by just 65 cases, and the 120-day process has become a 20-month average.

One feature has not changed. A Health Policy Watch investigation in 2023 found that in the most serious cases the final decision following an IOS investigation and report rests with one person: the Director-General. In other cases, decision rests with the WHO Regional Director  – who 

In May, WHO issued a new strategy, Zero Tolerance in Practice, for 2026–2029. It promises zero tolerance for misconduct, for retaliation and for inaction. A companion dashboard tracks disciplinary measures since 2022. Zero tolerance for inaction sits awkwardly beside a 20-month wait.

For six candidates, few answers

“Zero tolerance cannot be a slogan,” said Tamamyan in his post, which also provided a graphic analysis of data from the Internal Auditor’s report on “financial, sexual and harassment cases filed and addressed last year. “It has to be measurable: Do people trust the system enough to report? Are those who report protected? Do victims and survivors receive timely, effective support? And when something goes wrong, do we learn from it, or simply close the file?” 

Post on the misconduct data by WHO candidate for Director General, Gevorg Tamamyan

The six DG contenders who so far have remained mum on the issue include: Hans Kluge of Belgium, WHO Regional Director for Europe; Hanan Balkhy of Saudi Arabia, Regional Director for the Eastern Mediterranean; Indonesian health minister Budi Gunadi Sadikin; Qatar’s former health minister Hanan Al Kuwari; Spain’s María Neira, a WHO director for two decades; and China’s Song Li, former Director of China’s Commission on Maternal and Child Health. WHO publishes the official list in November.

Three are WHO insiders. Two run regions that appear on the dashboard: Balkhy’s has the largest open caseload of all, Kluge’s one of the smaller. Investigations are run centrally by IOS, not by regional offices, and cases are counted by where they arise, not by who is responsible. But both know the system from the inside.

On the campaign trail the talk has been of money and structure. Kluge has called WHO “overstretched, under-focused, and overly bureaucratic”. Balkhy has asked: “How do we use our money better?”

And other than Tamamyan, none of the candidates’ published statements reviewed for this article mentions investigations, internal justice or protection for staff who report abuse.

They will get their chance. The first Candidates’ Forum is on 18 November in Geneva. The Executive Board shortlists up to three names in January, and the World Health Assembly votes in May 2027.

The winner takes office on 16 August 2027. With the job comes the final say on every serious misconduct case in the organization, and a queue that is still getting longer.

Image Credits: WHO , WHO Misconduct against Persons Dashboard, WHO, Misconduct Dashboard , WHO, Internal Auditor Report, WHO, Internal Auditor's Report to WHA, WHO, LinkedIn/Gevorg Tamamyan.

When the United States turned on the World Health Organization (WHO) in 2020, Germany came to its defence. It led a reform that will raise assessed, unearmarked contributions in steps to half of the WHO’s core budget by 2030, so that the organisation can spend more on collective priorities and less on projects favoured by powerful donors.

The WHO lists Germany as its largest donor in 2020-21 and second largest since. Those days are ending. The Bundestag is considering a 2027 budget that grows by almost 6%, mostly for defence, while cutting the health ministry’s operational fund to strengthen international health by 15.3%, from €55.9 million to €47.33 million.

Of the $262 million Germany pledged to the WHO at the 2024 World Health Summit, only a third has been budgeted.

This week, Berlin hosts the World Health Summit again. The host arrives with no working strategy, no ministerial coordinator, no parliamentary committee and no candidate to lead the WHO. France has an ambassador for global health. Britain has a development minister who describes her job as “security through solidarity.” Germany has a summit.

How did the country that defended the WHO end up here? Olumide Abimbola of the Africa Policy Research Institute explains. Germany never had a grand plan for global health. It responded to Ebola, then COVID, spent the money and wrote its strategy afterwards. Under Scholz, the Chancellery stopped making the case for global health. Under Merz, global health has become a budget line to be cut.

That is not a choice the world’s third-largest economy should make quietly. Germany has the money, the institutions and, since the United States stepped back, the opportunity to be a force for good in global health. It also has a direct interest in doing so.

The global is already inside Germany

The World Health Summit, kicking off in Berlin on Sunday, has been hosted by Germany since 2009.

The stakes for Germany are not as abstract as they may seem. Mosquito-borne West Nile virus infections have been established in Germany since 2019. Two Frankfurt airport workers died of malaria this summer. German hospitals depend on doctors from Syria and Iraq and nurses from the Philippines and Kerala. Stuttgart’s Robert-Bosch-Krankenhaus employs staff from 86 nationalities and could not operate without them, its chief executive told me.

When COVID showed how closely Germany and the Western Balkans are bound by labour migration, part of the answer was to help build testing capacity there. A public health system, as an official at the Robert Koch Institute put it to me, cannot simply be switched on when it is needed. It has to exist before the crisis arrives.

Angela Merkel understood this. Her government put health on the G7 agenda in 2015 and the G20 agenda in 2017. Berlin secured the WHO’s pandemic intelligence hub, funded at €30 million a year; established a Global Health Hub for government, industry, science and civil society; and transformed the annual World Health Summit.

After Ebola, parliament expanded the mandate of the Robert Koch Institute. Its international centre became a technical partner to the public health institutes of Nigeria and Namibia and to Africa CDC.

Institutional drift

German Health Minister Jens Spahn and German Chancellor Angela Merkel during a joint press conference announcing the suspension of the use of the AstraZeneca COVID-19 vaccine.

But Germany did not make these institutions durable. They rested on a scientist chancellor, a physician chief of staff and a few motivated officials in the health ministry.  When the chancellor left, there was little to keep the policy moving.

Stella Merendino, an emergency nurse who sits for Die Linke on the Bundestag’s health committee, draws the lesson: “A global health policy shouldn’t depend on whether a handful of MPs or officials happen to care about it. It needs structures, funding and political accountability.”

Today, seven ministries divide global health between them. Health deals with the WHO, Development with international funds, Research with laboratories, Justice with patents and Trade with markets. The Federal Chancellery does not referee.

The Foreign Office’s coordinator for global health, created after Ebola, is gone. Health now sits in a division whose remit reads “economy, development, health and UN budget.” The Bundestag allowed its global health subcommittee to lapse after the 2025 election. Germany’s 2020 global health strategy runs to 2030. Its mid-term review, published last November, sets no clear milestones.

Andreas Wulf of Medico International was not surprised: “If you don’t have milestones and goalposts, what is the review doing?” The problem is not a lack of institutions. It is the lack of a clear direction for using them.

Working at cross-purposes

German Health Minister Nina Warken addresses the World Health Summit in Berlin.

In January, the development ministry’s reform plan ended bilateral health cooperation with partner countries and described the ministry as “very consciously using its policy of cooperation as a geopolitical instrument.” The RKI’s technical work remains, at roughly €15 million a year across all sources.

The coalition had already dropped the 0.7% aid target, for the first time in three decades. German funding for the WHO’s pandemic intelligence hub was halved last year and stays halved.

Recently, the Accra Reset, an initiative by African and Asian governments on health sovereignty, listed Gavi, the Global Fund and the Pandemic Fund among institutions to be consolidated or closed within a decade, and named the WHO as an institution that should continue.

Germany is funding the first group to the tune of €1 billion to the Global Fund for 2026–28, and €600 million to Gavi over five years. At the same time, it is cutting its voluntary contributions to the WHO; only the mandatory dues are untouched.

Germany is not withdrawing from global health. It is wavering when it should be leaning in.

Nowhere is the lack of a coherent strategy clearer than on medicines. Anna Holzscheiter of TU Dresden calls Germany’s position “organised hypocrisy”: in Geneva, Germany argues for equity and public goods; in trade negotiations over patents and technology transfer, she argues, it blocks measures that would make those principles possible. When pressed, Germany points the finger at Brussels.

The German trap

The latest World Health Summit opens at the storied InterContinental hotel in Berlin on Sunday,

The health ministry cannot resolve the issue because it does not control the relevant policy. A senior official there told me that the ministry is “not in charge of IP. There are two other ministries that are really giving us a hard time here.”

The contradiction is visible in Germany’s own record. In April 2020 Merkel said a COVID-19 vaccine should be “a global public good” and produced “in as many places in the world as possible.” In May 2021, the Bundestag rejected a patent waiver by 498 votes to 117.

BioNTech’s founder emailed Merkel his thanks the same day. By June, Merkel was telling parliament that a waiver was the wrong approach.

Christine Godt, professor of economic law at Oldenburg, sees a structural reason for this. Germany is a corporatist state: policy is negotiated with organised interests, and pharmaceutical companies are among them.

On lobbying, she says: “All means are used: advisory, drafting, conferences.” Godt notes that a patent alone does not make a vaccine available. The know-how to manufacture it matters too. Technology transfer has been part of international trade policy for decades but has never been effectively enforced.

Germany can attach conditions to public money when it chooses to. In September it gave Sanofi €400 million to keep producing insulin in Frankfurt, with obligations on output and stockpiles. It attaches no such conditions to the public money it gives for vaccines and medicines meant for the world.

Walter Bruchhausen, a medical historian, describes the problem simply: “If you just give money, you don’t influence policies. That is the German trap.”

The World Health Summit shows the pattern. Almost everyone I spoke to said the same: an event of government patronage and corporate sponsorship, with side meetings priced from €10,000 to €45,000, is not where policy is made.

The Summit agrees: decisions, it told me, “are made by the governments and institutions within their respective mandates”; it provides “a public platform for the announcement of commitments.” It does not know how many invited participants failed to get visas, and says equitable participation is “not a finished task.” A platform is not a plan. Berlin funds it while cutting its voluntary support for the WHO.

Three ways forward

Opening night at the World Health Summit in Berlin last year, which had some 3,000 registered attendees.

Give global health a mandate. Place an ambassador or coordinator in the Federal Chancellery, where the G7 and G20 sherpas already work, with the authority to coordinate the ministries, develop one strategy, and ensure it is implemented. In September, a study published by the Konrad-Adenauer-Stiftung, the foundation affiliated with the governing CDU, recommended exactly that, and the restoration of the parliamentary subcommittee.

Give the post measurable goals, an annual report to the Bundestag and independent evaluation. DEval already evaluates development policy and could do the same for global health. And involve people who work in the field: scientists, civil society and practitioners should help shape positions, not simply be invited to a round table twice a year or given a panel at the Summit.

Put conditions on publicly funded medical innovation. Public money should come with public-interest conditions, at home and abroad: a price ceiling, say, or a licence that allows others to use the technology. The pandemic agreement Germany negotiated obliges every party to adopt a policy on access conditions in publicly funded research, though it leaves the content to governments.

WTO rules, reaffirmed at Doha, let countries override patents to protect public health. Germany should use the room those rules provide rather than negotiate around it. The pharmaceutical strategy being rewritten in the Chancellery, due by year’s end, is the place to set these rules. Germany’s research ministry required similar conditions for neglected-disease grants in 2011. It never made them standard. 

Build partnerships for health sovereignty. The Accra Reset is one expression of a wider demand: governments across the Global South want control over their health financing and production. Germany should back the institutions those countries want strengthened: Africa CDC, national public health institutes, regulators and manufacturers, with the WHO setting common standards.

Germany’s most useful export may not be a patent but its Ausbildung ethos: the vocational and institutional training that builds skills and institutions which remain in place and grow locally. The RKI already works this way; Germany should expand that approach and let its partners define success.

Leadership that matters

Germany has long declined the role of a ‘leader’. That is changing.

Under pressure, it seems to be assuming that role for its armed forces, in the ambition to build “the strongest conventional army in Europe.” It has not yet assumed it for health.

A country that believes in international rules needs more than institutions. It needs to decide which institutions to defend, which norms to support and where to build lasting partnerships. National security also depends on human security. Germany is now increasing spending on the first while reducing capacity in the second.

The Bundestag will settle the budget in late November and can still restore the international health fund. The October Summit gives Germany a public stage to say what it wants to achieve. If it does not, the conclusion will be hard to avoid. There never was a plan. There was a chancellor. And she left.

About the author

Dr Unni Karunakara is a Senior Fellow at the Global Health Justice Partnership at Yale Law School in the US, and the Richard von Weizsäcker Fellow at the Robert Bosch Academy in Berlin. He was the interim director of the United Nations University International Institute for Global Health (UNU-IIGH) in 2024-2025, and international president of Médecins Sans Frontières (MSF) from 2010-2013.

Image Credits: World Health Summit, Clemens Bilan, World Health Summit, E. Fletcher/Health Policy Watch.

US Embassy Chargé d’Affaires Mich Coker (left) and Zambia’s Minister of Finance, Situmbeko Musokotwane, sign the MOU.

Zambia and the United States finally signed a bilateral health aid agreement on Thursday – after a 10-month delay as the US pushed for better access to the country’s minerals and changes to mining and agricultural regulations in exchange for health aid.

In 2024, 84% of Zambia’s HIV programme was funded by the US President’s Emergency Plan for AIDS Relief (PEPFAR) – and 1.3 million Zambians are on antiretroviral medicine to keep their HIV in check.

But Zambian Minister of Foreign Affairs Mulambo Haimbe told reporters at the signing ceremony that the country is negotiating a separate critical minerals agreement with the US

“There was this [agreement] on health and another on critical minerals, and we were saying that these need to be decoupled, and this has been done,” Haimbe said, adding that the minerals agreement is still being negotiated.

Zambia is one of the world’s biggest copper producers and also has large deposits of lithium and cobalt.

In terms of the health memorandum of understanding (MOU), the US “intends to provide more than $1.5 billion over the next five years to support priority health programs in Zambia including HIV/AIDS, tuberculosis, malaria, maternal and child health, disease surveillance, and infectious disease outbreak response and preparedness”, according to the US Mission In Zambia.

The Zambian government has pledged to increase its domestic health expenditures by $975 million over five years.

Zambia’s civil service will also take over frontline health care workers currently supported by the US government, and the country will also take over procuring health commodities.

The US funding will also support the scale-up of Zambia’s health data systems, including ensuring the “interoperability of key programmatic data for HIV/AIDS, TB, malaria, and disease outbreaks tracked at scale over the long term”.

‘Inspiring advocacy’ ensures changes

Health activists have hailed the MOU, pointing out that the US has committed $504 million more in funding than in the previous draft agreement and that health aid is no longer conditional on US access to minerals.

Zambia’s co-financing requirements have also been reduced from $243 million in the original MOU  to $154 million, and it is no longer tied to compulsory sharing of pathogen information with the US for 25 years.

“An inspiring, coordinated campaign of advocacy, pressure and outcry from Washington to Lusaka secured meaningful changes in this deal,” said Asia Russell, who heads Health GAP, a global medicine access project.

While there are “still weaknesses” in the new MOU, Russell said the changes showed that “solidarity, public and private pressure, and the refusal by civil society to accept HIV and global health funding being used to blackmail Zambia into handing over its mineral wealth were all components essential for securing progress in the face of an administration seemingly intent on dismantling ambitious, accountable, transparent, and data-driven global health programmes.”

In contrast, Zimbabwe failed to renegotiate the terms of its proposed MOU with the US, and has lost all aid – the catastrophic effects of which are already evident in the country’s malaria, tuberculosis, HIV and maternal and child programmes.

US Embassy Chargé d’Affaires Mich Coker (left) and Zambia’s Minister of Finance Situmbeko Musokotwane (centre) display signed copies of the U.S.-Zambia health MOU while Minister of Health Prof. Roma Chilengi (right) applauds.

Transactional demands

Last December, the US announced that it had reached agreement with Zambia on “a plan that aims to unlock a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms.”

However, while the US signed several MOUs with other African countries around this time, a deal with Zambia did not materialise.

The MOUs are part of the US State Department’s “America First Global Health Strategy”, which is based on making the US “safer, stronger, and more prosperous” – including by enabling US companies access to business opportunities in healthcare delivery.

In February, Zambia acknowledged that part of the proposed health aid deal with the United States “does not align with the country’s interests”.

In March, The New York Times reported that the US was planning to use health aid as a bargaining tool to force the country to give it access to critical minerals.

It quoted a leaked memo from the US State Department’s Africa Bureau to Secretary of State Marco Rubio, stating: “We will only secure our priorities by demonstrating willingness to publicly take support away from Zambia on a massive scale.”

After the leak, Dr Mike Reid, PEPFAR’s chief science officer, resigned in protest over Zambia’s treatment.

“When life-saving health assistance, often beyond the immediate capacity of partner countries, is conditioned on unrelated commercial or strategic objectives, something essential is lost,” Reid wrote in a Substack post shortly before resigning.

Crippling effect on HIV services

Zambian Health Ministry leaders have described the chilling effects on their health services after changes to US foreign aid following Donald Trump assuming the US presidency in January 2025.

These include a “drastic decrease in the HIV care workforce”, clinic closures, the cessation of “most HIV prevention services”,  “disrupted logistics, supply chains, [and] data systems”, and the “ interruption of key services such as HIV testing, laboratory diagnostics, and surveillance systems”.

“Electronic medical record systems, which had been run with PEPFAR support, became inaccessible, including in clinics that had implemented a fully digital workflow without paper-based records on-site,” the health ministry leaders noted in the journal, Open Forum Infectious Diseases.

“This occurred because data clerks were terminated and typically instructed to return laptops to the implementing partner’s headquarters; others left computer hardware on-site but without the opportunity to transfer passwords, accounts, or informatics skills to other staff.”

The Ministry leaders also modelled the impact of the disruptions, noting that just three months’ worth of disrupted services would cause an additional 34,550 deaths and 54 863 new HIV infections – something that the ministry will now need to factor into its plans as it scrambles to resume paused HIV prevention services.

*Story updated to include Health GAP comments and links to the old and new MOUs.

Thermal screening at a port of entry in the Democratic Republic of the Congo.

The Kenyan man who died of Ebola this week travelled extensively through the Democratic Republic of Congo (DRC) and Uganda and sought medical care from mid-September – passing through several airport health screenings without detection, even two days before he died.

Dr Wessam Mankoula, head of health emergencies for Africa Centre for Disease Control and Prevention (CDC), presented a map of the man’s travels at a media briefing on Thursday, showing that he sought medical treatment at health centres in Bondo and Kasangani in the DRC from as early as 17 September.

The deceased travelled through at least eight towns and cities and took three flights while sick, his final journey being a flight from Entebbe in Uganda to Nairobi on 3 October. He was picked up at Nairobi’s Jomo Kenyatta International Airport by a family member who drove him directly to Nairobi Hospital, where he died of Ebola two days’ later.

His medical records indicate that he had been suffering from fever and skin rash, and was diagnosed with a staphylococcal skin infection. There was some suggestion that he might have erroneously been diagnosed wth Rift Valley Fever, a mosquito-borne disease.

The journey taken by Kenya’s first Ebola patient in the weeks and days before his death, as mapped by health authorities in the DRC, Uganda and Kenya.

By the time he reached Nairobi, “he was suffering from fever, sore throat, muscle pain, and also bleeding in some of the infection sites,” said Mankoula.

The World Health Organization (WHO) reported on Wednesday that the man’s temperature had been recorded as normal when he was screened on two separate occasions.

Mankoula said he was possibly taking antipyretic medication, which had masked his fever and urged travellers to be transparent about their symptoms to ensure they did not endanger others.

“Please, if you start having any symptoms related to Ebola, if you have been in touch with any confirmed cases of Ebola, report this to the health authorities in your countries,” Mankoula urged.

“If you start having fever, please don’t try to take drugs to mask those symptoms so that you can start crossing the borders. 

“When you reveal if you have any symptoms or signs related to Ebola, you are not only preventing further spread to other countries, but also you are protecting yourself first. When you seek medical care early, we see an improvement in the outcome. When you delay in seeking medical care, this is when we see worse outcomes.”

“Africa CDC is calling for vigilance, not panic,” Mankoula stressed, saying that co-operation between the three affected countries has enabled authorities to map the man’s movements and start tracing his contacts.

In response, Kenya has activated its public health emergency operations centre and a national task force led by the Ministry of Health

Mankoula also called for the strengthening of health screening measures at countries’ points of entry and points of exit. 

“We have tried, through thermal screening, through some of the questionnaires in the countries, to track the history of the travellers and also if they have any symptoms or signs. So this is helping the countries to take quick measures to identify any suspected cases quickly and deal with this.”

More than 8,700 cases have been reported in DRC with 4,205 deaths – a 48% case fatality rate. There has been a 24% decrease in Ituri in the past three weeks, and a 19% decrease in Nord-Kivu, although conflict in the province is affecting surveillance. 

 

Image Credits: Twitter: @MoetiTshidi.

Chinese Foreign Ministry spokesperson Mao Ning briefing reporters in Beijing, where she confirmed Song Li’s nomination and reiterated China’s commitment to multilateralism.
Chinese Foreign Ministry spokesperson Mao Ning briefing reporters in Beijing, where she confirmed Song Li’s nomination and reiterated China’s commitment to multilateralism.

Beijing confirmed the nomination of National Health Commission official Dr Song Li for WHO Director-General on Thursday (8 October). The move expands the candidate field to seven amidst severe geopolitical ruptures shaking up the agency, with experts warning this move could further heighten superpower tensions.

In announcing the bid, Chinese officials framed the candidacy around global solidarity and strengthening multilateralism.

“China’s decision to nominate Dr Song Li reflects China’s aspiration to work for a global community of health for all and demonstrates China’s firm support for multilateralism,” Foreign Ministry spokesperson Mao Ning told reporters during a press briefing in response to a question by Reuters.

Song was nominated by the People’s Republic of China as WHO DG candidate.

“If elected, it will help the WHO play a more positive role in promoting the health and wellbeing of all humanity,” she added.

Until late last month, Song served as Director-General of the Department of Women and Child Health in China’s National Health Commission. She is a physician-scientist trained at Peking University and Harvard, bringing over two decades of experience in maternal policy, epidemic response, and WHO technical advisory groups.

Observers note Song’s technical focus contrasts with established ministerial and diplomatic figures in the race.

Song bid spotlights China’s financial weight

China ranks fourth in overall WHO funding for 2025-2026 at $320 million, driven overwhelmingly by mandatory assessed dues rather than voluntary contributions.
China ranks fourth in overall WHO funding for 2026-2027 at $320 million, due to the size of its mandatory assessed dues rather than voluntary contributions.

Song’s nomination by the People’s Republic of China comes as WHO manages massive budget cuts following the declared withdrawal of the United States in January 2025. Owing $280.9 million in unpaid arrears, WHA member states did not formally recognize the move at the May 2026 World Health Assembly.  But due to the unpaid dues, the US still faces the suspension of its voting rights at the 2027 World Health Assembly when the next WHO Director-General will be elected.

Global health policy experts observe that Beijing aims to fill the leadership void left by Washington’s withdrawal. According to official numbers on the WHO website, China’s total projected financial contribution to the WHO for the 2026-2027 biennium stands at $320 million through August, making it the largest state contributor in terms of assessed funding after the US withdrawal.

Among state donors, China’s funding is exceptionally concentrated in mandatory assessed dues, contrasting with traditional high-income donors from Europe, the Americas and western Asia, which distribute significant portions of their funding across core voluntary, thematic, and specified voluntary channels.

When compared against other major contributors, China ranks as the fourth-largest overall donor to the WHO, trailing only the Bill and Melinda Gates Foundation, the European Commission, and the World Bank, while sitting ahead of the United Kingdom, the GAVI Alliance, and Germany. While European Union Member States hold 27 votes in the WHA, the EU is not likely to vote en bloc, and two European nominees in the race could split their support.

Health Policy Watch reached out to the WHO asking to confirm the nomination and whether China had paid its dues for 2026 in full, but did not receive a response ahead of publication.

High geopolitical stakes for WHO

Lawrence Gostin doesn't see a global appetite for a Chinese DG candidate.
Lawrence Gostin doesn’t see a global appetite for a Chinese DG candidate.

One leading US global health expert voiced serious doubts that a Chinese candidacy will indeed shake up the final race because of the high geopolitical stakes for the WHO.

“In the aftermath of COVID-19, I do not think there is a global appetite for a Chinese candidate for WHO Director-General,” Lawrence Gostin, professor of global health law at Georgetown University, told Health Policy Watch.

“A Chinese candidate would heighten geopolitical tensions, putting the WHO in a difficult and vulnerable position,” Gostin added. “It would also make rejoining the WHO far more difficult for the US, even under a Democratic administration.”

The friction stems from increased geopolitical competition between the two superpowers and a lingering political fallout over COVID-19 transparency and initial outbreak reporting. Gostin noted that bipartisan opposition in Washington and a lack of civil society support create formidable hurdles for Song across both North America and Europe.

European reactions, however, remain more divided. While one senior European official warned that a successful Chinese bid would test the WHO’s fundamental legitimacy and independence, others were less alarmist, noting that Beijing’s diplomacy remains “very nuanced” and that China is viewed in Europe as a partner as well as a competitor.

Besides geopolitical scrutiny, China’s candidacy also faces structural UN hurdles regarding geographic distribution. With Dr Margaret Chan, a dual Canadian and Chinese national from Hong Kong, having served two terms as WHO Director-General from 2007 to 2017 and the Chinese national Qu Dongyu currently heading the Food and Agriculture Organization, member states may resist concentrating more UN agency leadership into the hands of one country.

BREAKING: China Has Nominated Candidate for WHO Director General Whose Name Remains Undisclosed

Note: This piece has been updated regarding Song’s position, Dr Margaret Chan’s term dates, and WHO budget cycle data.

Image Credits: Ministry of Foreign Affairs People’s Republic of China, WHO, WHO/HPW.

Jiho Cha, the Korean parliamentarian who is not running for WHO Director General

I sought to lead the World Health Organization (WHO) because the rules of intelligence are becoming the rules of health. My name will not be on the ballot. The responsibility remains. I will now work to organise the political and economic power needed to put intelligence at the service of humanity – and to keep it from turning against us.

Nominations for the next WHO Director-General closed on 24 September. Seven names are on the list. Mine is not. Those who received me as a candidate this summer deserve more than a sentence. The short version is that I chose a task I judged more urgent than the leadership of any single institution. The longer version is this essay, because the vision was never about me, and the question at its centre still awaits an answer from any of the six.

The question is simple to state, and it has been asked of every technology that has ever entered the clinic. The global health architecture is about to acquire a new layer of intelligence. For whom will it work, and under whose control? And, more urgently now: who will keep it from turning against us?

What the field taught me: Social, political and intelligence determinants of health

Access to nutritious, fresh foods, a critical determinant of health.

I came to that question slowly, through two kinds of work that rarely speak to each other.

More than 20 years ago, my first humanitarian posting as a physician was at Hanawon, the centre where people who have escaped North Korea spend their first months in the South. 

For three years I examined people who had crossed borders on foot and spent years in hiding. They arrived with tuberculosis and trauma, and with structural violence that had settled into the body. 

But my clinic was the end of their illness’s story, not its beginning. The social conditions that had made them ill lay years upstream: a famine that was political before it was agricultural, borders that turned flight into a crime, a stateless existence in which seeing a doctor meant risking deportation. What I treated were the sediments of a social order – the social determinants of health, arriving one body at a time.

With Médecins Sans Frontières, I followed those conditions back to their source: the borderlands people had fled, and later, with other humanitarian colleagues, to the Kashmir earthquake, the jungles of Papua New Guinea, and the refugee camps of the Democratic Republic of Congo. 

There I learned a lesson the textbooks phrase too politely. Illness in a crisis is rarely an accident of biology. It is the body’s registration of decisions made elsewhere. A woman denied even refugee status turns to a trafficker not because she misjudges the risk, but because every legal door has closed and return is the one certainty she cannot survive. The well-meaning people in white vehicles – I was one of them – too often arrive without the history that made the poverty they came to relieve, mistaking colonial residue for local misfortune.

Twenty years later, the citizens of Osan, a working city south of Seoul, sent me to the National Assembly, and there I learned the other half of the story. I watched the grief of Itaewon, where 159 people died in a single night, bent to political need and then erased. I watched the martial law decree of 3 December 2024 outlaw the Assembly in one clause and order striking doctors back to their wards in another – one text aimed at legislators like me and physicians like me.

And on the presidential campaign and the National Planning Committee, among the few who write national strategy, I learned how a line in my policy book becomes a ministry – or quietly a footnote no one answers for. 

Behind every failure of health care I had witnessed stood not a shortage but a choice: a political determinant. Power decides not only who is treated, but who is recognised as ill, and who has the power to judge whether or what treatment is provided.

‘Intelligence’ – the determinant behind the determinants

Meeting a child waste picker in Cambodia.

Between the social and political determinants, a third took shape, and it ran deeper than either. The resource on which health systems have depended longest, and which they have distributed most unequally, is neither medicine nor money. It is human judgement: the capacity to recognise who is ill, to decide what should be done, and to act. I call the conditions that govern the social distribution of that judgement the intelligence determinants of health. 

Across much of the world, a single nurse makes the decisions on which 10,000 lives may depend, with no one to consult and no second opinion within a day’s travel. Economists, scientists and policy experts are distributed across the world just as unevenly, and that distribution may itself be a determinant of the social and political conditions I had spent 20 years treating – the determinant beneath the determinants.

For the first time, a machine can carry a part of that judgement to places it has never reached. Governments and companies will decide within the next few years whether it reaches that nurse or only the hospitals that can pay – and they will decide much of it in private contracts whose terms no one outside the signing room will ever read: an old pattern in a new form, the determinants of health settled where the people they determine cannot see.

What I stood for: Climate, Health, and AI

Global AI hub launch in Seoul, Korea in May 2026

I wanted WHO to write the rules for this emerging layer of intelligence before the market did. In an emergency, the interval between a need and a standard is filled by whoever arrives first. WHO is the one institution every health ministry listens to, but the distance between a principle agreed in Geneva and a contract signed in a ministry is where the future of health care is being settled.

For a decade, since AlphaGo defeated the world’s best Go player,Lee Sedol, born on my mother’s island, I have worked on this new layer of intelligence from the outside: on AI-augmented health systems for low-resource settings, and more recently on Korea’s new societal model, the “AI Universal Basic Society” (AI UBS), which treats intelligence as public infrastructure for essential services, beginning with health care. 

In May, nine UN agencies including WHO, launched the Global AI Hub, a shared operational campus of the UN system, and in September Korea put both proposals before the General Assembly.

But WHO itself was not moving at the speed the moment demanded. Member states cut its base budget for 2026–27 from $5.3 billion to $4.2 billion, and development assistance for health fell to its lowest level in roughly 15 years. An organisation that has lost a fifth of its budget and many of its ablest people does not run towards new fields; it defends the ones it has. Meanwhile the largest technology companies were signing national-scale agreements for health and education, most on undisclosed terms.

So I did what a physician does when a referral is taking too long. I went to the patient myself. In July, I declared.

The core of my policy manifesto, One Doctor, Eight Billion Patients, is a single proposition: Universal Intelligence Coverage (UIC) for health. Universal health coverage asks whether people can receive care without being ruined by the cost. UIC asks whether judgement – human, machine or both – reaches everyone, and who answers when it fails. 

I proposed a “1.5-tier” model of primary health care: frontline workers equipped with AI decision support and supervised remotely by human professionals, with responsibility for diagnosis and treatment kept firmly with people.

Climate finance was the second strand. Less than 1% of it reaches health. I argued that a climate-resilient health system is itself a frontline mechanism of adaptation, and proposed that WHO use the Green Climate Fund accreditation it secured this year to channel roughly $1 billion into primary care without drawing a dollar from its shrinking core budget. 

The larger point was about dependence. Global health has run for decades on voluntary, earmarked money from a handful of governments, and the past two years have shown how quickly that base erodes when one of them turns inward. 

Blended finance is the way out: climate financing anchoring the public health layer, the private capital now pouring into the AI transition financing the intelligence layer above it, and public terms binding both to public goals.

Over 10 weeks I took these ideas to three continents – Africa, Asia and Europe – and to the leaders of their regional organisations. What we built together rests on one principle: regional health sovereignty – a decolonised global health architecture, powered by a new layer of intelligence and a new mechanism of finance. 

In Africa, it is “African AI for African health”, running on African infrastructure and answering to African law. In the Pacific Islands it is the “Pacific AI Initiative”, a regional platform for climate-resilient health systems. All want to build, not merely to buy.

African AI needs to run on African infrastructure and answer to African law.

After stepping back

I believe the diagnosis was right and the prescription was ready. I had been nominated by the Parliament as a WHO candidate for DG. But at the last minute, circumstances changed.  

The responsibility now passes to one of the other seven candidates, and I wish each of them well. Whoever becomes Director-General will find in me a partner. But the campaign taught me something I had not fully grasped when it began.

Meeting heads of government, frontier researchers and leaders of AI and biotechnology companies, I heard the same assessment with increasing frequency: the convergence of autonomous AI and biotechnology is entering a stage at which it could generate an existential threat of a new kind: a pandemic made by humans and machines together. 

The frontier laboratories now say so themselves: by their own published assessments, their latest models have reached the thresholds at which they could materially assist biological misuse, and the companies that build them ask publicly to be regulated. A risk I had been warning about for years was arriving far faster than I had expected. The window is closing: capability is advancing by the quarter, public control by the decade.

These are not two separate agendas. Bringing validated intelligence to a rural clinic and keeping unvalidated intelligence from harming the world are two answers to the same question – for whom, and under whose control, does intelligence work? 

But this answer lies beyond WHO’s reach. Responding to a pandemic, whatever its origin, is WHO’s mandate. Governing the roots of this risk – the race in frontier AI and its fusion with biotechnology – belongs to no institution at all. 

As with the nuclear competition of the last century, the world has no mechanism to slow a race centred on the United States and China, and the voice of industry overwhelms that of states. The world has visions and forums enough; it has no institution and no budget line for the AI society that is already arriving.

What it does have is the makings of a coalition. The Global South champions and the middle powers that hold technology and finance can, together, assemble the strength to shape that AI society. I have concluded that this work was more urgent than any position in any organisation. Over these months, leaders serving and former – in governments, international organisations, the media and academia – reached the same conclusion and asked me to help convene such a coalition. I In my own country, the expectation came from the highest level of government. I chose it.

A humanitarian learns early to go not where the doctors already are, but where there are none. The WHO post will be well filled; this work was more pressing, and almost no one was standing in line for it.

What I will do at the existential crossroads of the AI society

An individual viewing glowing numbers on a screen, symbolising artificial intelligence.
I will organise a global coalition to become an AI buyer, with the power to negotiate, purchase, legislate and govern.

Most proposals for AI governance begin with visions and institutions. I have sat in enough of those rooms to know how slowly they fill. Mine begins with a buyer – and in a market of scattered ministries, a buyer first has to be assembled. In a revolution led by private actors, the power a public actor can use fastest is to decide what it buys and on what terms.

Outside the few countries that build the intelligence infrastructure itself, the Global North will mostly use AI to replace human labour in systems that already exist, and substitution alone does not make a new economy.

In the Global South, the need has always outrun the supply–the clinic without a doctor, the classroom without a teacher, the household without a bank–and intelligence that can finally meet it creates a new economy rather than replacing one: a trillion-dollar market in which the buyer, not the supplier, should set the terms–and no one has yet organised a hundred fragmented buyers into one.

That is the work I will do, and the order is the strategy. Ask industry to regulate itself before you hold any market leverage, and the rules it writes will hold you. I will organise a coalition that can negotiate, purchase and legislate, govern–in that order.

First, a Planetary Intelligence Network, solidarity for sovereignty. Sovereignty over intelligence will not be won one ministry at a time; only a network of leaders who can decide can build it. I will convene it within months, not years. Any leader who shares these concerns – sovereignty over external intelligence, existential risk – has a seat. This is a network, not a bloc, and its first effect is simple: ministries that have always faced the same supplier alone begin to negotiate as one.

Second, New 3 by 5, collective purchasing power. Twenty years ago, Dr Lee Jong-wook set the world a target he called 3 by 5: three million people on HIV treatment by 2005. I propose a new 3 by 5: three million AI-augmented primary health care (PHC) workers within five years. We will augment first the community health workers, nurses and clinical officers who provide most first-contact care, raising their clinical and epidemiological capability toward that of a primary care physician, under remote human supervision. 

This is physician-level judgement arriving in three million places that have never had it. Connected across a continent, AI-augmented PHCs become a connected health system and pandemic preparedness–and a single buyer large enough to set terms. If a pandemic made by humans and machines ever begins, its first case will present not to a frontier lab but to one of them. Access and early warning are one investment.

Third, a Public Intelligence Compact, collective regulating power. A buyer of that size can set terms. The Compact is one set of conditions for any system that shapes a decision about a person in a public service: independent validation, data management under national law, continuity of service, the right to audit, transparent pricing. As a declaration, these are pieties; as a procurement rule, they are the law of the market. 

The Compact is neutral as to flag: any company that meets the terms is welcome. Sovereignty means a country can choose, question, change and, when necessary, leave the systems it uses. Its companion I call Firebreak – the line a fire does not cross. We cannot put out the fire of frontier development, but we buy the very models that could start one, and a buyer can set conditions today: no DNA synthesis order unscreened, no model in a public service unevaluated, no incident unreported. 

The Compact is the first line of defence, Firebreak the last, and the three million workers watching for the first spark are the sensors in between.

Fourth, a Public Intelligence Foundation and Existential Risk Council, a blended governance. This step evolves with purchasing power and regulating power. The Foundation is a shared operational platform with the global AI companies that will translate private AI back into public intelligence on the Compact’s terms. 

Beside it, and firewalled from it, stands the Existential Risk Council, independent of the foundation’s money, because a body that depends on industry cannot also judge its dangers. It will make independent evaluation of existential risks such as biological misuse–with incident reporting and synthesis screening–the price of entry for every model and the laboratory that trained it. The council will define itself against no state.

None of this replaces the United Nations. The network brings will, leverage and pace; the UN brings implementation and universality–the Global AI Hub’s agencies beyond health, and WHO for the clinical standard, which we will adopt, not rival. I know how this fails: a foundation captured by its funders, pilots that vanish with the donor cycle, and the oldest failure of all–help that arrives without asking the people it is for.

That is the work I am committing to lead.

Eight billion for one patient.

Jiho Cha is a humanitarian physician, global health scholar and Member of the National Assembly of the Republic of Korea, and co-chairs the Lancet Commission on Sea-Level Rise, Health, and Justice. For two decades, he has worked with marginalised populations in the Middle East, Africa and Asia, and with the displaced people caught between them. He was Professor of Humanitarian Studies at the University of Manchester and of AI and Future Strategy at KAIST, and designed Korea’s AI Universal Basic Society framework and the Global AI Hub, a joint campus of nine UN agencies. His policy manifesto, One Doctor, Eight Billion Patients, was prepared for his candidacy for WHO Director-General. The views expressed are his own.

Image Credits: Jiho Cha, Ron Lach via Pexels.

Dr Tedros addressing the media briefing.

The World Health Organization (WHO) has asked the Russian government for more information about the death of an employee at a Siberian plague research unit, including details about the laboratory tests conducted on her, the WHO Director-General told a media briefing on Thursday.

The WHO has also asked Russia for more details about the public health measures it has imposed, the health status of the woman’s contacts, and whether a second employee has been infected with “pneumonia of undetermined cause”, said Dr Tedros Adhanom Ghebreyesus.

This follows reports on Monday of the death of a 27-year-old female employee at the Irkutsk Anti-plague Research Institute of Siberia and the Far East – possibly of pneumonic plague.

The employee was hospitalised at Shelekhov Hospital on 29 September with symptoms of pneumonia, placed on a ventilator and died a few days later, according to media reports.

Tedros said that the WHO had sent queries to Russia on Saturday, and received a report on Wednesday that “no case of plague had recently been reported in the Irkutsk Oblast” where the research unit is, and that they had “placed about 200 [of the woman’s] contacts in quarantine”.

WHO has also offered Russia technical support related to “plague and lab biosafety and biosecurity”, Tedros said, adding that “we don’t yet have the full picture of this event, and we are not able to conduct a full risk assessment”.

Broken test tube?

Dr Maria Van Kerkhove, WHO director of epidemic and pandemic management.

Some media reports say the employee died after breaking a test tube in the laboratory, but Dr Maria van Kerkhove, WHO director of Epidemic and Pandemic Management, said that employees working in such laboratories would wear personal protective equipment (PPE) and be vaccinated against various diseases.

“We are following up on what type of PPE would be used, and under which conditions? What were they doing with these pathogens?” said Van Kerkhove.

“If there was a lab incident in this lab, there are procedures that must be followed in terms of the assessment that they do in the lab. There would be post-exposure prophylaxis, for example, for this individual. They would probably run tests, so there’s more to come as it relates to what actually happened,” she explained.

“What we have been told is that [Russia] has no case of plague registered in this area, and that no high threat pathogens were detected. So clearly, we would like more information to understand which laboratory tests were conducted, which pathogens were evaluated, and if this individual didn’t die from plague, then then how did she die?” Van Kerkhove added.

Plague is a severe, life-threatening infection caused by the bacterium Yersinia pestis and there are two types: bubonic and pneumonic. 

However, Van Kerkhove said there are thousands of cases of suspected plague every year around the world: “Between 2019 to 2025, 10 countries reported almost 4,000 suspected human plague cases and 423 deaths.”  

Central Asia is the hot spot, and people are infected by bacteria carried by small rodents.

“Sometimes there are small, sporadic outbreaks. Plague is caused by a bacteria. There are antibiotics that can treat this. So if anyone does have an infection with plague, it can be treated.”

International Health Regulations requirements

In terms of the International Health Regulations (IHR), WHO member states are legally obliged to assess public health risks and notify the WHO of any event that may constitute a public health emergency of international concern (PHEIC) within 24 hours of assessment.

Although the WHO submitted its queries to Russia in terms of the IHR on Saturday, it took the government more than three days to respond.

Dr Silvio Ciobanu from WHO’s European region and an IHR expert said countries have to answer four key questions in terms of the IHR: “How severe is the public health impact? Is it unusual and expected? Does it pose a risk of international spread? And does it pose a risk of trade or travel restrictions?”

Ciobanu added that the IHR are “very explicit that a response is expected within 24 hours, and then after that, state parties may require a little bit of extra time to collect all the additional information”.

Thick smog blankets the skyline of Bangkok, Thailand, in 2018.
Thick smog blankets the skyline of Bangkok, Thailand.

International development lenders committed $4.7 billion in 2024 to projects aimed explicitly at reducing air pollution, less than 1% of all international development finance, according to an annual analysis published Tuesday by the Clean Air Fund (CAF).

That was up 58% from $3.0 billion in 2023, nearly matching the 2022 peak of $4.8 billion. A broader measure, which also counts projects where cleaner air is a co- benefit, fell 6% to $28.7 billion, the first annual decline in five years. Five of the ten most polluted countries got less than $2 per citizen, and most of the money came in the form of loans, the analysis found.

Air pollution causes 7.9 million premature deaths a year, nine in ten of them in low- and middle-income countries, according to Health Effects Institute figures. It costs the equivalent of nearly 5% of global GDP, the World Bank estimates, and targeted policies could halve the number of people exposed to dangerous levels by 2040, with economic benefits of up to $2.4 trillion.

“Funding remains worryingly low, concentrated on a limited number of places, and misaligned with countries facing the greatest burden,” said Sean Maguire, executive director for strategic partnerships at CAF.

Top 10 polluted countries and their total air quality funding, 2024.

The data analysed stops in 2024, before the largest annual drop in development aid on record hit the following year. Development assistance for health fell by more than a fifth in 2025, to $39.1 billion, its lowest level in over 15 years, according to estimates by the Institute for Health Metrics and Evaluation (IHME). US health aid fell 67%.

Even before the cuts, air pollution drew little donor money relative to its toll, compared with causes such as food security, humanitarian relief or climate finance. Foundations gave it less than 0.1% of their global giving between 2019 and 2023, a separate CAF analysis found.

“Recent gains remain fragile,” the report says. “The challenge is whether these gains can be sustained and scaled amid shrinking aid budgets.”

The CAF report, produced with Climate Policy Initiative (CPI), tracks 2020-2024 commitments by development banks and donor governments. It excludes domestic budgets and private finance, and nearly nine in ten dollars it counts are loans.

“With development budgets under growing pressure, clean air objectives must be built into wider development investment, so every dollar works harder and delivers benefits for health, climate and economies at the same time,” Maguire said.

Most polluted countries left behind

South Asia receives nearly a third of all air quality funding (2020-2024).

Pakistan, Nepal, Myanmar, Cameroon and the Democratic Republic of Congo, five of the world’s ten most polluted countries, each received less than $2 per person in air quality funding in 2024. India, the second most polluted, was the exception, drawing 19% of all air quality funding that year.

“Air quality funding is not going where pollution exposure and health risks are greatest,” Maguire said.

Pakistan, ranked third for exposure to fine particulate matter (PM2.5), received about 3 cents per person. Between 2020 and 2024, it received $1.7 billion in what CAF calls fossil fuel-prolonging funding, nearly three times the $0.6 billion it received for all air quality projects combined.

Bangladesh, the most polluted country in the ranking, was the largest recipient of fossil fuel-prolonging funding over the five years, at $3.7 billion. Bangladesh’s fossil fuel funding fell 96% in 2024, to $113 million, the report found. Over the five years, it received $7.8 billion in air quality funding.

“Our analysis shows that money is not yet consistently following need, and that countries facing some of the highest pollution levels often have the least access to finance,” said Barbara Buchner, chief executive of CPI.

A wide tent for what counts as clean air funding

Projects that make no mention of air quality made up 84% of the air quality funding CAF counted in 2024.

CAF and CPI find these co-benefit projects through keyword searches of project descriptions in OECD and development bank data, projecting a clean air benefit from the type of project. The methodology captures investments in public transportation like buses, railways and metro lines, wastewater plants and networks, solid waste, household energy efficiency, food waste and soil health. It does not check whether individual projects actually cut pollution.

Transport accounted for 62% of all air quality funding over the five years, with railways and public transport alone making up $53 billion. Two loans worth $5 billion for a high-speed rail line between Mumbai and Ahmedabad made up 14% of South Asia’s air quality funding.

“Investment in railways, public transport and cleaner mobility is demonstrating how better connectivity and economic development can go hand in hand with cleaner air,” said Fu Lu, CAF’s regional director for Southeast Asia. “We need these benefits to be shared by many more people and places.”

Because co-benefit funding tracks wider lending for transport and infrastructure, its growth provides only mixed signals about whether funders are prioritizing clean air specifically.

Total air quality funding, co-benefit projects included, has held at 5.6% of international development funding across the last two five-year periods, while the outdoor share slipped from 0.8% to 0.7%.

The narrower outdoor category leans on similar projects. Under the keyword rules CAF published last year, a transport or water project counts as explicit clean air funding if its description also mentions air, health or exposure. Ten projects made up 53% of outdoor funding over 2020-2024, seven of them rail or public transport, mostly metro lines.

CAF itself found “no structural shift towards explicitly targeting air quality improvements” over the medium term.

Loans dominate co-benefit finance

Loans made up 89% of the $124.6 billion in air quality funding between 2020 and 2024, about $110 billion. Grants accounted for 7.7%. Co-benefit projects, which make no mention of air quality, made up $108.7 billion of the total.

Concessional funding fell from $19 billion to $12 billion, while non-concessional funding rose from $12 billion to $17 billion, 58% of the total. Concessional loans carry below-market interest but still have to be repaid. In 2024, the balance tipped further toward market-rate lending.

In CAF’s figures, which follow OECD aid classifications, concessional finance counts as aid, and aid budgets are shrinking, with the OECD projecting a further 5.8% drop in 2026. The reliance on loans in the donor landscape may put air quality funding beyond reach for countries already carrying heavy debts, according to CAF’s analysis.

Official development assistance from OECD donors fell 23.1% in real terms in 2025, to $174.3 billion, according to preliminary OECD data, as the United States cut its aid by 56.9%.

Across the global South, debt service is absorbing 45% of government revenue in 2025 and exceeds combined spending on education, health and social protection by 20%, according to Development Finance International’s Debt Service Watch.

A narrow measure of fossil fuel finance

About $1.2 trillion is expected to flow into oil, gas and coal in 2026, according to the International Energy Agency’s annual investment report. Governments plan to produce 120% more fossil fuels in 2030 than would be consistent with limiting warming to 1.5°C, according to the 2025 Production Gap Report.

The International Monetary Fund puts explicit fossil fuel subsidies at $725 billion in 2024. Implicit subsidies, three-quarters of them the unpriced cost of air pollution and climate damage, add $6.7 trillion. Removing both would mean 1.1 million fewer premature deaths from air pollution, the IMF estimates.

Against those sums, the report counted $4.7 billion in what it calls fossil fuel-prolonging development finance in 2024, down 48% from 2023, and said that put it level with outdoor air quality funding.

The report counts only international public development finance recorded in OECD data, and only projects that build polluting assets, such as power plants, pipelines and airports, or that promote polluting activities.

Private banks, domestic state spending, guarantees, most export credit and fuel subsidies fall outside it, and road building was dropped from the count this year.

G20 governments and multilateral development banks provided at least $47 billion a year in international public finance for oil, gas and coal between 2020 and 2022, according to the campaign group Oil Change International. About 65% came through export credit agencies, which CAF’s figures largely leave out.

The report warns that continued investment in long-lived fossil fuel assets risks “lock-in to a fossil fuel-dependent development pathway.” It also acknowledges that such funding can support energy access and security in developing countries.

Last year’s edition urged donors to end funding for fossil fuel-prolonging projects. None of this year’s five recommendations mentions fossil fuels.

Image Credits: urf/Getty Images via Canva.

Obesity is growing fastest among children and adolescents

The World Health Organization (WHO) released its first-ever guidelines to address how clinicians should manage obesity in children and adolescents, which include conditional recommendations for obesity medications and even surgery for children over the age of 10.

Since 1990, the number of children ages 5-9 years and adolescents 10-19 years living with obesity has quadrupled, skyrocketing from 2% to 8%. Upwards of 170 million children and adolescents now live with the chronic condition, which increases the risk of a host of medical complications, including type 2 diabetes and cardiovascular disease.

For children especially, obesity can come with stigmatisation, discrimination, and bullying, the WHO notes.

Obesity in children is projected to increase most rapidly in lower- and middle-income countries, where access to healthy foods and exercise now mirrors that in upper-income countries.

The growing global burden of overweight and obese children has led the WHO to issue guidelines for what it terms “person-centered” care, which is a combination of nutrition, physical activity, behavioral management, and in some cases, medication or even surgery.

The WHO recommendations are based on an evaluation of 35 scholarly review articles, but research is still evolving, especially for pharmaceutical-based interventions in children.

Childhood obesity management
WHO’s childhood obesity management recommendations.

Conditional recommendations for medication

For children under 10, the WHO does not recommend obesity drugs or bariatric surgery. Instead, the focus should be on structured interventions such as healthy eating, physical activity, and behavioral change, Dr Luz Maria De Regil, director of the WHO’s Department of Nutrition and Food Safety, told a press conference in Geneva this week.

If this three-pronged approach fails for adolescents, WHO recommends that, in some instances, obesity drugs could be used if the child is mentally and physically prepared. 

Several blockbuster drugs now dominate the weight loss market. In the US, nearly one in five adults reported taking a GLP-1 drug such as Ozempic or Weygovy at some point for diabetes or weight loss. 

The WHO notably added GLP-1s to its recommended guidelines for obesity treatment for adults in 2025, a step in what the global health agency said is a “conditional” sign of approval for the cutting-edge medications that have become so popular.

The picture for children is a bit more complicated, WHO scientists said. While pharmaceutical giants Novo Nordisk and Eli Lilly are both running clinical trials in children as young as six, the WHO had little research to draw on to assess whether the drugs meet the bar of safety or efficacy for children under 10. 

But that hasn’t stopped prescriptions, as a study published in the journal Pediatrics reported that the number of children aged eight to 11 on GLP-1s “increased sharply” between 2019 and 2026. Their study estimates that out of a cohort of over 3.5 million children with obesity – and without diabetes – roughly 20,000 children were prescribed GLP-1s. 

Dr Luz Maria De Regil, director of WHO’s Department of Nutrition and Food Safety, speaking at a press conference in Geneva.

A recent analysis from Lurie Children’s Hospital in Chicago found that GLP-1s may be linked to nutritional deficiencies in children, most notably a lack of vitamin D. The researchers found that only 5% of pediatric patients on GLP-1s received nutritional counseling. 

“As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks during periods of rapid growth and pubertal development,” said Dr Justin Ryder, the study’s senior author and vice chair of research for the Department of Surgery at Lurie Children’s Hospital. 

Ryder, who is also an associate professor of surgery and pediatrics at Northwestern University, commented in a press release that the study highlights the need for proactive nutrition counseling as children are growing, as any deficiencies early in life could have lasting effects.

There are also concerns about adherence to the drug regimen and long-term effects when children start so young, said Dr Laurence Grummer-Strawn, the unit head of Nutrition and Food Safety Action at WHO. 

He cautioned that because obesity is a long-term chronic condition, it is especially important to understand these drugs in children before recommending them. That is why the guidelines don’t focus on or recommend a specific weight loss drug.

“WHO recognizes this is a rapidly evolving field,” said De Regil. Her team is monitoring data as it becomes available on long-term anti-obesity medications in children.

Surgery in severe teen cases

Bariatric surgery also falls under a conditional recommendation for adolescents 10-19 years old. With only a handful of studies to analyze, the team acknowledged that the balance of benefits and harms “are not entirely clear.”

Again, WHO stresses that the decision to undergo an invasive surgery requires “physical and mental maturity” for those with the most severe forms of obesity. 

“That’s why it’s conditional,” said Dr Maria Nieves Garcia Casal, a WHO scientist in the Department of Nutrition and Food Safety. 

The WHO only recommends surgery for those with a Body Mass Index (BMI) for age greater than four standard deviations above the WHO growth reference median, which is a high threshold for a surgical intervention.

Nutrition, exercise, mental health

Ultra-processed food is a staple diet for Mexican 10-year-old Ricky and his mother, Alicia. The WHO recommends dietary interventions to manage childhood obesity.

The guidelines stress that obesity management goes beyond simple weight loss, involving a combination of structured dietary, exercise, and behavior-changing interventions that work best when tailored to the individual.

Digital technologies, including active video games or phone apps that encourage movement,  could also help children manage their obesity, although the WHO’s recommendation is conditional as excessive screen time should be limited. 

The recommendations also emphasise the importance of addressing mental health alongside obesity: “Anxiety, depression, low self-esteem and emotional dysregulation can contribute to unhealthy eating behaviours, physical inactivity and social withdrawal, and children and adolescents living with obesity may experience stigma and bullying that harm their emotional well-being,” the WHO notes in a media release issued alongside the guidelines. 

Worrying trends in low- and middle- income countries

Obesity is on the rise globally and across all regions; however, the rate of increase has mostly plateaued in developed nations, while it is increasing in low- and middle-income countries.

In much of Latin America, sub-Saharan Africa, Caribbean and Pacific Island nations, and South and Southeast Asia, the rate of childhood obesity is rapidly accelerating. In some countries with already high burdens of childhood obesity, like in the US and the Middle East, that rate is mostly stagnant.  

A Nature study published earlier this year noted that the increase in obesity rates in children is happening across regions and afflicting most low- and middle-income countries: Tanzania, Rwanda, Ethiopia, Nepal, Bangladesh, Saudi Arabia, Malaysia, and Chile all saw steady or rapid increases in the past three decades.

“These highly varied dynamics suggest that the social, economic and technological trends that influence the availability, affordability and use of different foods may have helped control the rise in obesity in high-income countries,” the study authors write, “but require policy interventions in low-income and middle-income countries.”

Childhood obesity
Obesity in children is accelerating most rapidly in low and middle-income countries, per a May 2026 Nature article.

Prevention and treatment go ‘hand in hand’

While the guidelines focus on treating obesity in children, the WHO acknowledged the role of addressing a child’s environment, including unhealthy food options in schools, persistent marketing of unhealthy food to children, and the lack of safe places to play. 

Dr Laurence Grummer-Strawn, unit head of Nutrition and Food Safety Action, argued that much of what remains outside of a child’s individual control has deep consequences for their obesity risk. These include whether a child was breastfed, their junk food marketing environment, and their school environment. 

“Countries need to create environments that make healthy diets and physical activity accessible and affordable, while ensuring that children and adolescents already living with obesity can access high-quality care free from stigma and discrimination,” said De Regil. 

“We need to prevent obesity wherever we can, and ensure that those already living with obesity receive the care and support they need.”

Image Credits: Commons , WHO, UNICEF, Nature/ NCD-RisC.

A Chinese candidate reportedly is waiting in the wings to join the race for WHO Director General.

China has nominated a prominent Chinese health official for WHO Director General in the 2027 elections, multiple diplomatic sources have confirmed to Health Policy Watch. 

But there are mixed reports about who that candidate actually may be. Some high-level sources have cited Song Li, a senior Chinese Communist Party official who mounted a failed bid for the post of Regional Director for  WHO’s Western Pacific Regional Office (WPRO) in 2023. 

Others, however, have denied that she is a candidate, noting that after losing the 2023 election, Beijing wants a stronger contender for a global race.

Song Li, Director-General, Department of Women & Children’s Health, National Health Commission (NHC), People’s Republic of China.

Either way, China’s immense and still growing geopolitical range of influence from the Western Pacific to Southeast Asia and Africa means it could mount a serious campaign that could permanently shift the delicate balance of power at the WHO following the withdrawal of the United States from the organization last year.  

WHO election rules hinder transparency

The picture is complicated by the fact that under WHO rules, public disclosure of Song, and any other potential candidate from China or elsewhere, is only required at the end of this month, after the conclusion of the WHO European Regional Committee Meeting on 29 October, the last in the series of WHO regional conferences of member states.  

This is according to the WHO election process rulebook, which creates a one-month gap between the formal submission of nominations to WHO by member states and public disclosure. 

Six prospective candidates have already been announced on the WHO election website, as reported by Health Policy Watch  after nominations formally closed on 24 September.

But their names were published at the discretion of the sponsoring countries, WHO has explained. Nominations don’t have to be formally disclosed until the end of the final WHO Regional Committee meeting, according to the WHO handbook of rules, a spokesperson told Health Policy Watch. 

The Permanent Mission of China to the UN in Geneva did not respond to several Health Policy Watch queries about the DG nomination, sent over the past few days.

Quietly professional – but still a Communist Party official

Song, Director-General of the Department of Women and Child Health in China’s National Health Commission, has sat on several WHO technical committees related to maternal and newborn health.  

At the time of the 2023 campaign for WPRO RD, she was described as “quietly professional” by global health veteran Mukesh Kapila, in a Health Policy Watch analysis of that election campaign. 

“But will China refrain from influencing her so that she can function genuinely independently? Chinese incumbents in international organisations often remain under obligation to their own authorities, and can even be summoned home if they displease their masters,” Kapila, a columnist and Health Policy Watch board member, asked at the time. 

‘No surprise’ for Europeans

Others are asking similar questions now.

“It would come as no surprise if China were to put forward their candidate,” a senior European global health policymaker said in an interview last week with Health Policy Watch on the reports of a China candidate for DG, speaking on the margins of the European Health Forum – Gastein.  “They see a chance to fill the power void that the United States has left behind.”

However, the diplomat expressed doubts as to whether Beijing could mobilize sufficient votes to actually win the race.

While acknowledging the risk of increased polarization within the world’s premier health agency, he described Beijing’s diplomatic approach as “very nuanced,” noting that while Europeans view China as a competitor in some areas, it’s also a partner in others.

Concerns in Washington DC more likely

As the US has withdrawn from WHO, China is filling the vacuum.

But the prospect of a Chinese Director-General is likely to raise very different concerns in Washington as compared to Europe, says Kieran Bligh, a former WHO staff member doing doctoral studies on global health leadership at George Washington University and a Health Policy Watch fellow.

“The bigger risk is that Washington vacates the space and China fills it,” he says. “The WHO could increasingly become a tool used against US interests while (Washington) has no seat at the table due to the US withdrawal from the agency.”

In an early September Bligh predicted that Beijing would soon make a public move in the Director-General race, stating: “China is doing what any serious global power would do: making sure it has influence over who leads the world’s health agency.”

From Asia’s Belt and Road to Central Africa

A coltan mine in M-23 Rubaya, North Kivu, Democratic Republic of Congo. China also plays a key role in the refinement and distribution of this vital mineral.

The potential for China to muster significant votes to any candidate it mounts is significant, observers say. For one thing, China has recently been appointed to the WHO Executive Board (EB) of 34 member states. China joined WHO’s EB governing body in May 2026, after securing the seat at the 2025 WPRO Regional Committee, as reported by Health Policy Watch. 

In February 2027, the Executive Board will select three finalists for the race – out of the bloc of declared contenders. 

Africa’s 54 WHO member states often vote in a bloc on many major WHO policy issues. Forty-seven African states are affiliated with WHO’s African Region, while another seven North and Horn of Africa nations are members of the Eastern Mediterranean Region of the WHO. 

China’s outsized financial and political influence in Africa extends everywhere on the continent. Chinese firms, for instance, control 70-80% of the copper and cobalt mining in Ebola-stricken Democratic Republic of Congo, including not only legitimate ventures but hundreds of illegal extraction sites in South Kivu province alone where impoverished African families labour. It also plays a key role in distributions of other vital minerals like coltan, critical for electronics, and for which DRC produces 40% of the worlds supply. Coltan is mined artisanally and smuggled illegally over the border to Rwanda and then onward to China and the United Arab Emirates for refining. 

Child laborers in one of the hundreds of illegal mines in the DRC’s South Kivu province – most of which are operated by Chinese nationals.

Across the continent, China has invested nearly $200 billion in port, rail and road projects, as well as modern agrobusinesses, which it is increasingly operating as well. Local African markets are rife with cheap imports of Chinese consumer goods.  

China is the world’s largest official creditor and the single largest bilateral source of official-sector financing to the developing world, according to AidData. Similarly, the massive Belt and Road Initiative has extended Beijing’s economic and political influence across Asia, Africa, the Middle East, Europe and even Latin America.

“Money matters,” Bligh says. “Those influences do not disappear when governments walk into a secret ballot [at the Executive Board level, or later, at the full World Health Assembly], and debt exposure can be powerful leverage.” 

He argues that if a Chinese candidate were to win the DG race, burning issues like the origins of the SARS-CoV2 virus would likely be buried forever, and WHO collaborations in future independent inquiries could be suppressed. 

To date, China has never responded to WHO requests for blood samples or genetic sequences of the virus from the first patients infected in Wuhan or detailed information about the status of animals sold at Wuhan’s wet markets – where the virus first emerged in late 2019. 

Nor has it provided detailed data on the research work and biosafety conditions in the Wuhan Institute of Virology. These are the two leading sources from which scientists believe the virus first began to circulate widely. 

Wuhan’s Huanan seafood market was shuttered early in 2020, down after COVID emerged in the vicinity. But China’s government has provided little data to WHO  on the early days of the SARS-CoV2 virus circulation among animals or humans.

WHO needs competent, credible leadership most of all

Magda Robalo, president and co-founder of The Institute for Global Health and Development (IGHD), prefers to see the glass half full rather than empty. 

“Supporters might argue this reflects the growing importance of Asian economies in global health. Critics might worry about political influence over sensitive issues involving transparency, disease reporting, or geopolitical disputes,” the former Guinea-Bissau Minister of Health told Health Policy Watch.

“WHO needs a competent, credible and strong leader, able to build consensus among its 194 member states and reform WHO to focus on science, its core strengths and functions, irrespective of nationality or sex,” she said. 

“One cannot ignore the fact that current geopolitical tension, mistrust, fragmentation and erosion of multilateralism will certainly increase scrutiny on candidates’ ties and citizenship. A Chinese DG candidate could be seen by some countries as reinforcing China’s influence in international institutions. Health is political after all.”

“[But] China has significantly expanded its role in global health over the past two decades through investments in health systems, disease surveillance, vaccine production, and health aid, particularly in Africa and Asia,” she concluded.

Already the largest WHO contributor and heading FAO 

Dongyu Qu – FAO DG: ‘ We’re not allowing you to play the game here of human rights.’

Long overshadowed by high-income WHO member states in the Americas, Europe and Asia, China is today WHO’s largest state contributor in terms of assessed dues, paying the sum of $137.8 million in 2026.

At the 2025 Assembly, Vice-Premier Liu Guozhong pledged an additional $500 million over five years, with a line aimed at Washington: “The world is now facing the impacts of unilateralism and power politics.” 

However, the WHO notes that the pledged additional amount is still  “to be confirmed”. 

The US, meanwhile, owes $280.9 million in membership arrears and faces suspension of its vote at the very Assembly that will elect the next DG. 

China already holds the top job at another major UN specialized agency. Dongyu Qu, a Chinese national nominated by Beijing, has served as Director-General of the UN Food and Agriculture Organization since 2019 and is now in his second term.

Dongyu recently came under fire for his scathing comments about other senior FAO officials “playing the game of human rights” at the Rome-based agency.  “We’re not allowing you to play the game here of human rights,” he was filmed saying at a recent FAO assembly. “Of course, human rights is very important. But we have the human rights agency in Geneva. If you want to take care of that, go there.” 

Aside from Dongyu’s views, the fact that he holds the DG position at a UN agency is an informal barrier to a Chinese nominee winning the election for WHO DG, as countries have typically preferred that powerful leadership roles are distributed amongst UN member states, rather than concentrated with one nation. 

Meanwhile, the secrecy surrounding the definitive list of candidates also opens the way for a closet game of poker, in which a country with an undisclosed candidate could potentially leverage commitments from one of the other, publicly declared competitors for post-election policies or appointments in exchange for withdrawing quietly from the race. 

Not the first time China has held senior leadership roles at WHO

Dr Margaret Chan, WHO Director General from 2006-2016

But this would not at all be the first time that senior posts were awarded based on nationalities and not only competencies. 

In fact, a DG’s appointments of his or her Assistant Directors Generals and other senior managers are often payback for support received during the campaign. 

It would not be the first time, at all, that a Chinese national held a senior position at WHO. From May 2023 – Jun 2025, Ailan Li served as an Assistant Director-General, Universal Health Coverage, Healthier Populations under Dr Tedros Adhanom Ghebreyesus.

Following the 2025 WHO budget crisis leading to staff reductions, Li’s position was eliminated. She is now the WHO Representative to Thailand.

Moreover, a Chinese national, Margaret Chan, first elected in November 2006 and holding the Director General’s post from 2007 to 2017, the first ever to do so. 

But Chan was a native of Hong Kong and a senior health official there during the first SARS outbreak – a period that preceded China’s brutal 2020 crackdown on dissent, Hong Kong’s free media and its semi-autonomous governance, which the island had seen since 1997. Chan was also a dual Canadian national.

Secrecy adds to potential leverage against other candidates

The candidacy of any high-level member of the Chinese Communist Party, if it were to materialize, would still be unprecedented in terms of the level and scope of influence it would open up to Beijing.  

Equally unprecedented is the amount of leverage that a shadow candidate nominated by Beijing or by any other member state could wield on other DG competitors, between now and the end of the month, when full disclosure will be required by the WHO rules.  

The technical loophole that has emerged, therefore, is in how the horses leave the gate. This is a muddy start to a race that most global health pundits describe as a crossroads that could determine the very survival of WHO as a robust, independent global health entity in the UN family.  

Correction: an earlier version of this story said that Margaret Chan was WHO Director General from 2006-2016, when in fact she was elected in November, 2006 but only took over the position in 2007, serving until 2017. 

Image Credits: Wikipedia Commons, WHO, ©The Rudin Group , MONUSCO/Sylvain Liechti, Harvard-Kennedy School, Deutsche Welle.